A medical crusade devoted to the pharmaceutical and surgical alteration of children’s bodies is projected to become a $5 billion industry in the United States by 2030, according to a market research report by Grand View Research (pdf).
However, this lucrative commitment to the gender-affirming care model is not without dissent.